Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;29(2):178-182.
doi: 10.1007/s00399-018-0567-x. Epub 2018 May 14.

[Syncope in hypertrophic (obstructive) cardiomyopathy]

[Article in German]
Affiliations
Review

[Syncope in hypertrophic (obstructive) cardiomyopathy]

[Article in German]
Hubert Seggewiß et al. Herzschrittmacherther Elektrophysiol. 2018 Jun.

Abstract

Hypertrophic cardiomyopathy is the most common genetic cardiac disease. The most important pathophysiological finding is dynamic (outflow tract) obstruction of the left ventricle in about 70% of affected patients. Especially in younger patients, an increased risk of sudden cardiac death has been observed. Syncope and presyncope-in addition to extremely variable cardiac symptoms (dyspnea and angina)-are common. The etiology of syncope is complex. The most important aspect for diagnosis is a detailed history regarding the accompanying circumstances of the syncope. In principle, an attempt must be made to distinguish between rhythmogenic and hemodynamic causes. Diagnostic work-up should be performed under the criteria of a possible prognostic-with implantation of an implantable cardioverter-defibrillator (ICD) in patients at increased risk of sudden cardiac death-and symptomatic therapy. Depending on the underlying morphology and the experience of the surgeon, percutaneous septal ablation and operative myectomy are complementary options for symptomatic treatment if medical therapy with beta-blockers and/or verapamil is inadequate.

Keywords: Heart diseases; Myectomy; Obstruction left ventricle; Percutaneous septal ablation; Sudden cardiac death.

PubMed Disclaimer

References

    1. Circulation. 2006 Nov 21;114(21):2232-9 - PubMed
    1. Dtsch Med Wochenschr. 2001 Apr 12;126(15):424-30 - PubMed
    1. Eur Heart J. 2008 Jan;29(2):270-6 - PubMed
    1. Lancet. 1995 Jul 22;346(8969):211-4 - PubMed
    1. Tex Heart Inst J. 1997;24(4):372-5 - PubMed

Substances

LinkOut - more resources